Sanjay K. Murthy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sanjay K. Murthy has a total of 337 co-authors. Here are the top co-authors by number of shared publications:
- Eric I. Benchimol
Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, Canada; ICES, Toronto, Canada; Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children (SickKids), Toronto, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
21 shared publications - Charles N. Bernstein
University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Canada
12 shared publications - Gilaad G. Kaplan
Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada
10 shared publications - Laura E. Targownik
Division of Gastroenterology and Hepatology Department of Medicine Mount Sinai Hospital University of Toronto Toronto Ontario Canada
10 shared publications Alain Bitton
Division of Gastroenterology and Hepatology, McGill University Health Centre IBD Centre, McGill University , Montréal, Quebec , Canada
9 shared publications- M. Ellen Kuenzig
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids) , Toronto, ON
9 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
The VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease
Current guidelines recommend pancolonic chromoendoscopy (pCE) over white light endoscopy (WLE) alone for colorectal neoplasia (CRN) detection in individual
- 17 July 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessThe VISION-AI Trial: protocol for a pragmatic randomized controlled non-inferiority trial comparing artificial intelligence-guided colonoscopy to pancolonic chromoendoscopy for neoplasia detection in adults with colorectal inflammatory bowel disease
Current guidelines recommend pancolonic chromoendoscopy (pCE) over white light endoscopy (WLE) alone for colorectal neoplasia (CRN) detection in individual
- 16 April 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (11) , 1586-1587
Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
- 16 April 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (11) , 1586-1587
Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
- Open Access
- 11 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (6) , 859-873
A Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease
Background: Trends in extra‐digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management. Aims: To study temporal trends and contemporary risks of ED cancers in individuals with and without IBD. Methods: Using population‐level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age‐sex‐matched controls (1:10) without IBD between 1994 and 2020. We modelled age‐sex‐standardised annual cancer incidence (per 100,000 person‐years) over time by first‐order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi‐Poisson regression. Results: The average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, −0.380, 0.599) but declined among 1,109,190 matched controls (−1.39%/year; 95% CI, −1.57, −1.21). Among those with IBD, AAPC was significant for non‐Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010–2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer‐related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls. Conclusions: ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer‐related mortality is higher among those with CD, relative to matched controls.
- 11 November 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (6) , 859-873
Open AccessA Population‐Based Matched Cohort Study of Extra‐Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease
Background: Trends in extra‐digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management. Aims: To study temporal trends and contemporary risks of ED cancers in individuals with and without IBD. Methods: Using population‐level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age‐sex‐matched controls (1:10) without IBD between 1994 and 2020. We modelled age‐sex‐standardised annual cancer incidence (per 100,000 person‐years) over time by first‐order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi‐Poisson regression. Results: The average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, −0.380, 0.599) but declined among 1,109,190 matched controls (−1.39%/year; 95% CI, −1.57, −1.21). Among those with IBD, AAPC was significant for non‐Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010–2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer‐related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls. Conclusions: ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer‐related mortality is higher among those with CD, relative to matched controls.
- Open Access
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (6) , 260-266
Temporal trends in 30-day and 90-day hospital readmission rates among individuals with inflammatory bowel diseases in Ontario, Canada: a population-based study
Background: Individuals with inflammatory bowel diseases (IBD) are at increased risk of repeated disease-related hospital admissions, some of which may be preventable with targeted outpatient interventions. We assessed population-level trends in the rates of IBD-specific hospital readmission within 30 and 90 days of index hospitalization among those with Crohn’s disease (CD) and ulcerative colitis (UC) during a period marked by major changes to IBD management. Methods: We accessed Ontario health administrative datasets to study CD (2002-2017) and UC (2004-2020) patients hospitalized for IBD-specific indications. We compared IBD-specific 30-day and 90-day hospital readmission rates across 4 (UC) and 5 (CD) year time periods using multivariable logistic regression, controlling for age, sex, comorbidities, residential setting, household income, hospital type, and clustering of admissions within patients. Results: Among CD patients, 30-day readmission rates decreased from 9.7% to 7.4%, and 90-day rates decreased from 16.0% to 14.1% between 2002-2007 and 2012-2017 periods. There was a higher likelihood of 30-day readmission during 2002-2007 (adjusted odds ratio [aOR] 1.32; 95% CI, 1.16-1.50) and 2007-2012 (aOR 1.15; 95% CI, 1.01-1.32), and of 90-day readmission during 2002-2007 (aOR 1.14; 95% CI, 1.03-1.26), as compared to 2012-2017. Among UC patients, readmission rates remained stable across time periods. Conclusion: Inflammatory bowel disease-related early rehospitalization risk has declined over time among individuals with CD but not among individuals with UC.
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (6) , 260-266
Open AccessTemporal trends in 30-day and 90-day hospital readmission rates among individuals with inflammatory bowel diseases in Ontario, Canada: a population-based study
Background: Individuals with inflammatory bowel diseases (IBD) are at increased risk of repeated disease-related hospital admissions, some of which may be preventable with targeted outpatient interventions. We assessed population-level trends in the rates of IBD-specific hospital readmission within 30 and 90 days of index hospitalization among those with Crohn’s disease (CD) and ulcerative colitis (UC) during a period marked by major changes to IBD management. Methods: We accessed Ontario health administrative datasets to study CD (2002-2017) and UC (2004-2020) patients hospitalized for IBD-specific indications. We compared IBD-specific 30-day and 90-day hospital readmission rates across 4 (UC) and 5 (CD) year time periods using multivariable logistic regression, controlling for age, sex, comorbidities, residential setting, household income, hospital type, and clustering of admissions within patients. Results: Among CD patients, 30-day readmission rates decreased from 9.7% to 7.4%, and 90-day rates decreased from 16.0% to 14.1% between 2002-2007 and 2012-2017 periods. There was a higher likelihood of 30-day readmission during 2002-2007 (adjusted odds ratio [aOR] 1.32; 95% CI, 1.16-1.50) and 2007-2012 (aOR 1.15; 95% CI, 1.01-1.32), and of 90-day readmission during 2002-2007 (aOR 1.14; 95% CI, 1.03-1.26), as compared to 2012-2017. Among UC patients, readmission rates remained stable across time periods. Conclusion: Inflammatory bowel disease-related early rehospitalization risk has declined over time among individuals with CD but not among individuals with UC.
- Open Access
- 23 June 2025
- Published by Catalytic Health in Canadian IBD Today
- p. 13–20
Using Immunosuppressive Therapies to Treat Inflammatory Bowel Diseases (IBD) in the Post‑Cancer Setting
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD), and ulcerative colitis (UC), are chronic immune-mediated inflammatory disorders (IMID) affecting both intestinal and extraintestinal organs. Chronic intestinal inflammation causes multifocal DNA damage, increasing the risks of intestinal cancers. While the widespread use of effective biologic and small molecule therapies and intensified immune modulating (IM) regimens in recent years may have contributed toward declining colorectal cancer risks, these treatments could have introduced unexpected cancer risks in organs not directly affected by IBD due to reduced immune surveillance. Among individuals with IBD, the use of thiopurines has been frequently associated with risks of lymphoma, non‑melanoma skin cancer (NMSC), and cervical cancer. Several large studies have also reported increased risks of lymphoma, and melanoma associated with anti-tumour necrosis factor alpha (anti‑TNF) therapies, although other studies have not shown these associations. A randomized controlled trial (RCT) in elderly individuals with rheumatoid arthritis (RA) and cardiovascular risk factors reported a slightly increased all‑cause cancer risk with the non-selective Janus kinase inhibitor (JAKi), tofacitinib. Other immunosuppressive (IS) therapies, including methotrexate, anti-interleukin (IL)‑12/23 or anti‑IL-23 therapies, anti-α4β7 integrin therapy, JAK-1-selective inhibitors (upadacitinib), and sphingosine-1-phosphate receptor agonists, have not been associated with increased cancer risks to date. However, some of these newer therapies have only been available for a few years. Given the low absolute risk of treatment‑related cancers, controlling underlying IBD with IS therapies is typically prioritized to improve quality of life and reduce IBD-related complications. However, the decision to start or continue IS therapy in individuals with current or prior malignancy is more complex, as immune surveillance may be more crucial for these patients. Clinical trials generally exclude patients with a cancer history, which limits the available evidence on cancer recurrence risks associated with specific therapies. Additionally, some cytotoxic chemotherapy regimens can control IBD for prolonged periods, suggesting that additional immunomodulation may be unnecessary, and potentially harmful, during cancer treatment. Conversely, hormonal, radiation, and immune checkpoint inhibitor therapies have been associated with increased risks of IBD flares. Therefore, a careful and collaborative approach with oncologists is essential for the optimal management of IBD patients diagnosed with cancer. Recently, the European Crohn’s and Colitis Organization (ECCO) and the American Gastroenterological Association (AGA) released practice recommendations regarding the use of IS therapies in individuals with IBD in the post‑cancer setting. This review summarizes the evidence regarding cancer risks associated with specific IBD therapies in this context and presents a management approach based on both scientific and practical considerations.
- 23 June 2025
- Published by Catalytic Health in Canadian IBD Today
- p. 13–20
Open AccessUsing Immunosuppressive Therapies to Treat Inflammatory Bowel Diseases (IBD) in the Post‑Cancer Setting
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD), and ulcerative colitis (UC), are chronic immune-mediated inflammatory disorders (IMID) affecting both intestinal and extraintestinal organs. Chronic intestinal inflammation causes multifocal DNA damage, increasing the risks of intestinal cancers. While the widespread use of effective biologic and small molecule therapies and intensified immune modulating (IM) regimens in recent years may have contributed toward declining colorectal cancer risks, these treatments could have introduced unexpected cancer risks in organs not directly affected by IBD due to reduced immune surveillance. Among individuals with IBD, the use of thiopurines has been frequently associated with risks of lymphoma, non‑melanoma skin cancer (NMSC), and cervical cancer. Several large studies have also reported increased risks of lymphoma, and melanoma associated with anti-tumour necrosis factor alpha (anti‑TNF) therapies, although other studies have not shown these associations. A randomized controlled trial (RCT) in elderly individuals with rheumatoid arthritis (RA) and cardiovascular risk factors reported a slightly increased all‑cause cancer risk with the non-selective Janus kinase inhibitor (JAKi), tofacitinib. Other immunosuppressive (IS) therapies, including methotrexate, anti-interleukin (IL)‑12/23 or anti‑IL-23 therapies, anti-α4β7 integrin therapy, JAK-1-selective inhibitors (upadacitinib), and sphingosine-1-phosphate receptor agonists, have not been associated with increased cancer risks to date. However, some of these newer therapies have only been available for a few years. Given the low absolute risk of treatment‑related cancers, controlling underlying IBD with IS therapies is typically prioritized to improve quality of life and reduce IBD-related complications. However, the decision to start or continue IS therapy in individuals with current or prior malignancy is more complex, as immune surveillance may be more crucial for these patients. Clinical trials generally exclude patients with a cancer history, which limits the available evidence on cancer recurrence risks associated with specific therapies. Additionally, some cytotoxic chemotherapy regimens can control IBD for prolonged periods, suggesting that additional immunomodulation may be unnecessary, and potentially harmful, during cancer treatment. Conversely, hormonal, radiation, and immune checkpoint inhibitor therapies have been associated with increased risks of IBD flares. Therefore, a careful and collaborative approach with oncologists is essential for the optimal management of IBD patients diagnosed with cancer. Recently, the European Crohn’s and Colitis Organization (ECCO) and the American Gastroenterological Association (AGA) released practice recommendations regarding the use of IS therapies in individuals with IBD in the post‑cancer setting. This review summarizes the evidence regarding cancer risks associated with specific IBD therapies in this context and presents a management approach based on both scientific and practical considerations.
- 5 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 410-423
Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study
INTRODUCTION: Owing to the therapeutic ceiling associated with inflammatory bowel disease (IBD) therapies, some patients may require 2 advanced therapeutic agents, known as advanced combination treatment (ACT) to control disease or treat associated extraintestinal manifestations (EIMs). METHODS: We included adult patients with IBD from 9 Canadian centers treated with either 2 biological therapies, a biological plus an oral small molecule, or 2 small molecules. Indications for ACT were the following: (i) refractory IBD, (ii) uncontrolled immune mediated diseases, and (iii) uncontrolled EIMs. Primary outcomes were cumulative rates of clinical and endoscopic response and remission at 6 and 12 months. Secondary outcomes included serious adverse events and infections. Cox-proportional hazard analyses identified independent predictors of treatment effectiveness. RESULTS: We included 105 IBD patients (76 Crohn's disease, 29 ulcerative colitis) with median age 35 years (Interquartile Range 35.4–40.8). At baseline, 39% had perianal involvement, 58% had failed at least 3 advanced therapies, and 40% had previous surgery. The primary reason for ACT was refractory IBD (63.8%), with the add-on approach used in 97.1% cases. The most frequent combination was antitumor necrosis factor + anti-integrin. At 12 months, cumulative rates of clinical and endoscopic response were 60.0% and 32.4%, respectively, and remission rates were 29.5% and 28.6%. Perianal disease was associated with reduced clinical remission (hazard ratio [HR] = 0.33, 95% confidence interval [CI]: 0.17–0.65, P = 0.001) and endoscopic response (HR = 0.42, 95% CI: 0.12–0.50, P = 0.001). Longer disease duration (HR = 0.96, 95% CI: 0.92–0.99, P = 0.035) and baseline steroid use (HR = 0.39, P = 0.006) was associated with reduced clinical remission. Serious adverse events and infections occurred in 12.4% and 7.6% of patients, respectively. DISCUSSION: ACT was effective in achieving clinical and endoscopic outcomes in patients with refractory IBD or concomitant immune-mediated diseases/EIMs, with favorable safety profile.
- 5 June 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 410-423
Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study
INTRODUCTION: Owing to the therapeutic ceiling associated with inflammatory bowel disease (IBD) therapies, some patients may require 2 advanced therapeutic agents, known as advanced combination treatment (ACT) to control disease or treat associated extraintestinal manifestations (EIMs). METHODS: We included adult patients with IBD from 9 Canadian centers treated with either 2 biological therapies, a biological plus an oral small molecule, or 2 small molecules. Indications for ACT were the following: (i) refractory IBD, (ii) uncontrolled immune mediated diseases, and (iii) uncontrolled EIMs. Primary outcomes were cumulative rates of clinical and endoscopic response and remission at 6 and 12 months. Secondary outcomes included serious adverse events and infections. Cox-proportional hazard analyses identified independent predictors of treatment effectiveness. RESULTS: We included 105 IBD patients (76 Crohn's disease, 29 ulcerative colitis) with median age 35 years (Interquartile Range 35.4–40.8). At baseline, 39% had perianal involvement, 58% had failed at least 3 advanced therapies, and 40% had previous surgery. The primary reason for ACT was refractory IBD (63.8%), with the add-on approach used in 97.1% cases. The most frequent combination was antitumor necrosis factor + anti-integrin. At 12 months, cumulative rates of clinical and endoscopic response were 60.0% and 32.4%, respectively, and remission rates were 29.5% and 28.6%. Perianal disease was associated with reduced clinical remission (hazard ratio [HR] = 0.33, 95% confidence interval [CI]: 0.17–0.65, P = 0.001) and endoscopic response (HR = 0.42, 95% CI: 0.12–0.50, P = 0.001). Longer disease duration (HR = 0.96, 95% CI: 0.92–0.99, P = 0.035) and baseline steroid use (HR = 0.39, P = 0.006) was associated with reduced clinical remission. Serious adverse events and infections occurred in 12.4% and 7.6% of patients, respectively. DISCUSSION: ACT was effective in achieving clinical and endoscopic outcomes in patients with refractory IBD or concomitant immune-mediated diseases/EIMs, with favorable safety profile.
- Open Access
- 24 January 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (2) , 76-82
A multivariable prediction model to stratify risk of 90-day rehospitalization among adults with ulcerative colitis
Background: Individuals with ulcerative colitis (UC) are frequently re-hospitalized for persistent or recurrent severe disease flares. Accurate prediction of the risk of early re-hospitalization at the time of discharge could promote targeted outpatient interventions to reduce this risk. Methods: We conducted a retrospective study in adults with UC admitted to The Ottawa Hospital between 2009 and 2016 for an acute UC-related indication. We ascertained candidate demographic, clinical, and health services predictors through medical records and administrative health databases. We derived and bootstrap validated a multivariable logistic regression model of 90-day UC-related re-hospitalization risk. We chose a probability cut point that maximized Youden’s index to differentiate high-risk from low-risk individuals and assessed model performance. Results: Among 248 UC-related hospitalizations, there were 27 (10.9%) re-hospitalizations within 90 days of discharge. Our multivariable model identified gastroenterologist consultation within the prior year (adjusted odds ratio [aOR] 0.11, 95% confidence interval [CI], 0.04-0.39), male sex (aOR 3.27, 95% CI, 1.33-8.05), length of stay (OR 0.94, 95% CI, 0.88-1.01), and narcotic prescription at discharge (OR 1.96, 95% CI, 0.73-5.27) as significant predictors of 90-day re-hospitalization. The optimism-corrected c-statistic value was 0.78, and the goodness-of-fit test P-value was .09. The chosen probability cut point produced a sensitivity of 77.8%, specificity of 80.9%, positive predictive value (PPV) of 33.0%, and negative predictive value (NPV) of 96.7% in the derivation cohort. Conclusions: A limited set of variables accessible at the point of hospital discharge can reasonably discriminate re-hospitalization risk among individuals with UC. Future studies are required to validate our findings.
- 24 January 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (2) , 76-82
Open AccessA multivariable prediction model to stratify risk of 90-day rehospitalization among adults with ulcerative colitis
Background: Individuals with ulcerative colitis (UC) are frequently re-hospitalized for persistent or recurrent severe disease flares. Accurate prediction of the risk of early re-hospitalization at the time of discharge could promote targeted outpatient interventions to reduce this risk. Methods: We conducted a retrospective study in adults with UC admitted to The Ottawa Hospital between 2009 and 2016 for an acute UC-related indication. We ascertained candidate demographic, clinical, and health services predictors through medical records and administrative health databases. We derived and bootstrap validated a multivariable logistic regression model of 90-day UC-related re-hospitalization risk. We chose a probability cut point that maximized Youden’s index to differentiate high-risk from low-risk individuals and assessed model performance. Results: Among 248 UC-related hospitalizations, there were 27 (10.9%) re-hospitalizations within 90 days of discharge. Our multivariable model identified gastroenterologist consultation within the prior year (adjusted odds ratio [aOR] 0.11, 95% confidence interval [CI], 0.04-0.39), male sex (aOR 3.27, 95% CI, 1.33-8.05), length of stay (OR 0.94, 95% CI, 0.88-1.01), and narcotic prescription at discharge (OR 1.96, 95% CI, 0.73-5.27) as significant predictors of 90-day re-hospitalization. The optimism-corrected c-statistic value was 0.78, and the goodness-of-fit test P-value was .09. The chosen probability cut point produced a sensitivity of 77.8%, specificity of 80.9%, positive predictive value (PPV) of 33.0%, and negative predictive value (NPV) of 96.7% in the derivation cohort. Conclusions: A limited set of variables accessible at the point of hospital discharge can reasonably discriminate re-hospitalization risk among individuals with UC. Future studies are required to validate our findings.
- Open Access
- 25 June 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (11) , 2275-2287
A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease
INTRODUCTION: To study digestive system cancer risks in individuals with inflammatory bowel diseases (IBDs) in the biologic era. METHODS: We used population-level administrative and cancer registry data from Ontario, Canada, (1994–2020) to compare people with IBD to matched controls (1:10 by sex and birth year) on trends in age-sex standardized cancer incidence and risk ratios of incident cancers and cancer-related deaths. RESULTS: Among 110,919 people with IBD and 1,109,190 controls, colorectal cancer incidence (per 100,000 person-years) declined similarly in people with ulcerative colitis (average annual percentage change [AAPC] −1.81; 95% confidence interval [CI] −2.48 to −1.156) and controls (AAPC −2.79; 95% CI −3.44 to −2.14), while small bowel cancer incidence rose faster in those with Crohn's disease (AAPC 9.68; 95% CI 2.51–17.3) than controls (AAPC 3.64; 95% CI 1.52–5.80). Extraintestinal digestive cancer incidence rose faster in people with IBD (AAPC 3.27; 95% CI 1.83–4.73) than controls (AAPC −1.87; 95% CI −2.33 to −1.42), particularly for liver (IBD AAPC 8.48; 95% CI 4.11–13.1) and bile duct (IBD AAPC 7.22; 95% CI 3.74–10.8) cancers. Beyond 2010, the incidences (and respective mortality rates) of colorectal (1.60; 95% CI 1.46–1.75), small bowel (4.10; 95% CI 3.37–4.99), bile duct (2.33; 95% CI 1.96–2.77), and pancreatic (1.19; 95% CI 1.00–1.40) cancers were higher in people with IBD. DISCUSSION: Cancer incidence is declining for colorectal cancer and rising for other digestive cancers in people with IBD. Incidence and mortality remain higher in people with IBD than controls for colorectal, small bowel, bile duct, and pancreatic cancers.
- 25 June 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (11) , 2275-2287
Open AccessA Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease
INTRODUCTION: To study digestive system cancer risks in individuals with inflammatory bowel diseases (IBDs) in the biologic era. METHODS: We used population-level administrative and cancer registry data from Ontario, Canada, (1994–2020) to compare people with IBD to matched controls (1:10 by sex and birth year) on trends in age-sex standardized cancer incidence and risk ratios of incident cancers and cancer-related deaths. RESULTS: Among 110,919 people with IBD and 1,109,190 controls, colorectal cancer incidence (per 100,000 person-years) declined similarly in people with ulcerative colitis (average annual percentage change [AAPC] −1.81; 95% confidence interval [CI] −2.48 to −1.156) and controls (AAPC −2.79; 95% CI −3.44 to −2.14), while small bowel cancer incidence rose faster in those with Crohn's disease (AAPC 9.68; 95% CI 2.51–17.3) than controls (AAPC 3.64; 95% CI 1.52–5.80). Extraintestinal digestive cancer incidence rose faster in people with IBD (AAPC 3.27; 95% CI 1.83–4.73) than controls (AAPC −1.87; 95% CI −2.33 to −1.42), particularly for liver (IBD AAPC 8.48; 95% CI 4.11–13.1) and bile duct (IBD AAPC 7.22; 95% CI 3.74–10.8) cancers. Beyond 2010, the incidences (and respective mortality rates) of colorectal (1.60; 95% CI 1.46–1.75), small bowel (4.10; 95% CI 3.37–4.99), bile duct (2.33; 95% CI 1.96–2.77), and pancreatic (1.19; 95% CI 1.00–1.40) cancers were higher in people with IBD. DISCUSSION: Cancer incidence is declining for colorectal cancer and rising for other digestive cancers in people with IBD. Incidence and mortality remain higher in people with IBD than controls for colorectal, small bowel, bile duct, and pancreatic cancers.
- 7 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 166 (5) , 728-729
How Close Is Close Enough? Improving Observational Study Design to Compare the Effectiveness of Health Interventions
- 7 March 2024
- Published by Elsevier in Gastroenterology
- Vol. 166 (5) , 728-729
How Close Is Close Enough? Improving Observational Study Design to Compare the Effectiveness of Health Interventions